|Over a month ago|
OPTI Medical Systems receives CE mark for OPTI SARS-CoV-2 RNA PCR test kit » 07:0306/0506/05/20
OPTI Medical Systems, a…
OPTI Medical Systems, a subsidiary of IDEXX Laboratories, announced that it has received the CE mark certification in the European Union for its OPTI SARS-CoV-2 RT-PCR laboratory test kit for the detection of SARS-CoV-2, the virus that causes COVID-19. This announcement follows earlier validation of the test by the Institut Pasteur of France as well as Emergency Use Authorization by the United States FDA. Additionally, the FDA has granted EUA for the new OPTI DNA/RNA Magnetic Bead Kit for nucleic acid extraction from respiratory samples to be used with the OPTI SARS-CoV-2 RT-PCR test kit, which enables OPTI Medical Systems to provide laboratories with a complete OPTI Medical Systems-manufactured workflow solution for COVID-19 testing.
Fly Intel: After-Hours Movers » 18:2405/2605/26/20
STNE, OOMA, TSCO, HEI, CHRS, ESNT, PTEN, JACK, IDXX, BMY, VSAT, KEYS, SBLK, RPAY, FVRR
Check out this evening's…
Idexx Laboratories sees 'meaningful improvement in U.S. clinical visit trends' » 17:0205/2605/26/20
Idexx Laboratories provided an update on U.S. Companion Animal Market Trends through Friday, May 22nd. "We are monitoring the impact of the COVID-19 pandemic on U.S. companion animal practice visit trends, including the effect of stay-at-home and social distancing policies to prevent the spread of COVID-19, as well as the related prioritization of sick and emergency testing at veterinary clinics. With an additional four weeks of activity since our last update, we continue to see meaningful improvement in U.S. clinical visit trends across major regions, with overall U.S. clinical visits, non-wellness visits and wellness visits surpassing prior year levels in the most recent week ended May 22nd."
OPTI Medical receives FDA EUA for OPTI SARS-CoV-2 RNA PCR test kit » 07:3805/0705/07/20
OPTI Medical Systems, a…
OPTI Medical Systems, a subsidiary of IDEXX Laboratories, announced that the United States FDA has granted Emergency Use Authorization for the OPTI SARS-CoV-2 RT-PCR laboratory test kit for the detection of SARS-CoV-2, the virus that causes COVID-19. This announcement follows earlier validation of the test by the Institut Pasteur of France.
Idexx Laboratories announces business update amid COVID-19 pandemic » 06:4604/3004/30/20
The primary impacts of…
The primary impacts of the COVID-19 pandemic have been seen in Idexx's CAG business. While veterinary care is widely recognized as an "essential" service for pet owners, and veterinarians continue to deliver essential medical care for sick and injured pets, stay-at-home and social distancing policies being deployed to combat the spread of COVID-19, and prioritization of sick and emergency testing at veterinary clinics, have resulted in a decrease in companion animal clinical visits, including delay of elective procedures and wellness visits. These types of trends have contributed to year-over-year declines in demand for Idexx's products and services during this period, with varying impacts by region and diagnostic testing modality. These impacts are dynamic, and the company has seen meaningful improvement in clinical visit and diagnostic testing trends over the most recent two-week period ended April 24, driven by U.S. and International regions where COVID-19 case management efforts have progressed further and where stay-at-home and social distancing policies have been moderated.
Idexx Laboratories withdraws FY20 guidance amid COVID-19 unpredictability » 06:4404/3004/30/20
The company is…
The company is withdrawing its previously announced FY20 guidance due to the unpredictability of the duration and the magnitude of impacts from the COVID-19 pandemic on veterinary service providers.
Idexx Laboratories reports Q1 EPS $1.29, consensus $1.20 » 06:4304/3004/30/20
Reports Q1 revenue…
Reports Q1 revenue $626.34M, consensus $617.41M. "We are pleased to report excellent first quarter financial results, supported by continued double-digit organic gains in CAG Diagnostics recurring revenues, despite late-quarter impacts from the expansion of COVID-19-related stay-at-home policies and social distancing procedures. These results reflect continued strong underlying demand globally for companion animal healthcare," said Jay Mazelsky, the company's president and CEO. "We have seen near-term impacts on veterinary practices related to the COVID-19 pandemic and have been closely monitoring the effect of social distancing policies and industry care guidelines on our customers. IDEXX has continued to provide high levels of service delivery and product support for its customers during this time, while advancing key steps to protect the safety and health of its employees, ensure business continuity and mitigate the near-term impacts on demand for IDEXX products and services. The pet-owner bond is stronger than ever, and IDEXX's strategy, opportunity and fundamentals remain intact, supported by our innovative product portfolio and talented global team. We are very well-positioned for a strong recovery in the highly attractive and resilient companion animal healthcare market. I am extremely proud of the way our team is working together to respond during this time and thank them for their extraordinary commitment to our Purpose."
Idexx Laboratories checks on placements look soft, says Cleveland Research » 09:3004/2704/27/20
Cleveland Research analyst Rob Eich said his checks suggests Idexx in-lab diagnostic equipment placements were soft at the end of Q1 and continue to be weak in April due to COVID-19. He believes placements will take several quarters to return to growth and thinks that visits likely remaining pressured for the foreseeable future will continue to impact consumables, rapid assay, and reference lab growth. Eich keeps a Neutral rating on Idexx Laboratories shares.
Idexx Laboratories makes pet test for COVID-19 available to veterinarians » 07:3904/2004/20/20
IDEXX Laboratories announced the availability of the IDEXX SARS-CoV-2 RealPCR Test for pets. IDEXX is launching the test in response to customer demand and growing evidence that in rare cases pets living with COVID-19 positive humans can be at risk for SARS-CoV-2 infection. The test will be available to veterinarians in North America this week and will continue to roll out across most of the world in the coming weeks, enabled by IDEXX Reference Laboratories, the company's worldwide network of more than 80 laboratories.
|Over a quarter ago|
Stifel animal health analysts to hold an analyst/industry conference call » 13:5503/1903/19/20
TRUP, KIN, CVT, IDXX, ZTS
Analysts discuss the…
Analysts discuss the Animal Health Industry and their expectations that there will be some impact to the industry growth in the 2Q20 due to COVID-19 on an Analyst/Industry conference call to be held on March 19 at 2:30 pm.